Middle East and Africa In Situ Hybridization Market Research Report – Segmented By Technique, Application, End User & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) – Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2024 to 2029)

Updated On: January, 2024
ID: 6799
Pages: 145

MEA In Situ Hybridization Market Size (2023 to 2028)

The size of the Middle East and Africa In Situ Hybridization Market was worth USD 51.80 million in 2023 and estimated to be growing at a CAGR of 5.15%, to reach USD 66.59 million by 2028.

The In-situ Hybridization market in the MEA is expected to be driven by the increasing prevalence of chronic diseases such as cancer and genetic disorders. Also, the Increasing adoption of ISH techniques and the growing demand for molecular diagnostic tools. In addition, the increasing awareness about companion diagnostics tests in situ hybridization and extensive research and development activities are proving the way for the new market entrants.

However, in the recent past, the growing demand for molecular diagnostics is significantly adopting the ISH technologies, which is expected to boost the market growth, as this technique is used for localizing and detecting DNA and RNA sequences in the cells. In addition, the demand for increased need for clinical diagnosis is growing due to the constant increase in the rate of chronic diseases, increasing the demand for in-situ hybridization in the market.

The market for in-situ hybridization is further rising because of technical improvements for establishing creative and efficient techniques and increasing public awareness about the availability of growing diagnostics and therapies for this chronic condition. On the other hand, the increase in the investment and fundings from government and non-government organizations in research and development activities are expected to encourage market growth. Furthermore, the use of DNA probe-based diagnostics to diagnose disorders presumed to be caused by infections or bacteria has increased. Consequently, the market is expected to be fueled by rising incidences of genetic diseases, solid tumors, leukemia, autism, and other syndromes throughout the forecast period.

However, the strict government rules and regulations and stringent approval process for introducing the product hampers the market growth. On the other hand, the presence of various alternative tests and therapies available in the market affects the demand for in-situ hybridization in the European market. In addition, the increase in the high cost of the tests, lack of skilled and trained individuals for operating devices, and conducting a test for diagnosis are majorly impeding the in-situ hybridization market growth.

This research report on the MEA In Situ Hybridization Market has been segmented and sub-segmented into the following categories.

By Technique:

  • FISH
  • CISH

By Application:

  • Cancer Diagnosis
  • Neuroscience
  • Cytology
  • Infectious Disease

By End User:

  • Molecular Diagnostic Laboratories
  • Academic and Research Institutions

By Type:

  • DNA
  • RNA

By Product:

  • Instruments
  • Probes & Kits

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

In 2020, The Kingdom of Saudi Arabia and the United Arab Emirates held a majority share of revenue due to well-established diagnostic companies, the high prevalence of cancer, coupled with the strong adoption of molecular diagnostic tools by researchers in this region. The cancer incidence rates doubled between 2002 and 2020, with 4.99 and 2.99 cases per 100,000 inhabitants in 2002 to 8.99 and 6.55 cases per 100,000 inhabitants in 2019. These regional markets face significant competition as many players are offering ISH probe technology for various applications.

South Africa is projected to show lucrative growth due to increased public investment to support the development of biotech and pharmacology sectors, a large number of a growing population who are more prone to chronic diseases. In addition, a high rate of chronic cases will increase the need for personalized diagnostic kits and medications.

The regional market in Egypt is estimated to grow at a moderate CAGR during the studied period owing to a large number of clinical research institutes and biotechnological centers, population with cancer and genetic disorders, awareness about the various disease which aims for detection at an early stage and favorable government funds and camps.


A few of the major companies operating in the MEA in situ hybridization market profiled in this report are Abbott Laboratories, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Exiqon A/S (Denmark), BioGenex Laboratories, Inc. (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), and Bio SB Inc. (U.S.).

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1200

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample